Cargando…

Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment

Liposomes are well-known nanoparticles with a non-toxic nature and the ability to incorporate both hydrophilic and hydrophobic drugs simultaneously. As modern drug delivery formulations are produced by emerging technologies, numerous advantages of liposomal drug delivery systems over conventional li...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikolova, Maria P., Kumar, Enamala Manoj, Chavali, Murthy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608678/
https://www.ncbi.nlm.nih.gov/pubmed/36297630
http://dx.doi.org/10.3390/pharmaceutics14102195
_version_ 1784818831704719360
author Nikolova, Maria P.
Kumar, Enamala Manoj
Chavali, Murthy S.
author_facet Nikolova, Maria P.
Kumar, Enamala Manoj
Chavali, Murthy S.
author_sort Nikolova, Maria P.
collection PubMed
description Liposomes are well-known nanoparticles with a non-toxic nature and the ability to incorporate both hydrophilic and hydrophobic drugs simultaneously. As modern drug delivery formulations are produced by emerging technologies, numerous advantages of liposomal drug delivery systems over conventional liposomes or free drug treatment of cancer have been reported. Recently, liposome nanocarriers have exhibited high drug loading capacity, drug protection, improved bioavailability, enhanced intercellular delivery, and better therapeutic effect because of resounding success in targeting delivery. The site targeting of smart responsive liposomes, achieved through changes in their physicochemical and morphological properties, allows for the controlled release of active compounds under certain endogenous or exogenous stimuli. In that way, the multifunctional and stimuli-responsive nanocarriers for the drug delivery of cancer therapeutics enhance the efficacy of treatment prevention and fighting over metastases, while limiting the systemic side effects on healthy tissues and organs. Since liposomes constitute promising nanocarriers for site-targeted and controlled anticancer drug release, this review focuses on the recent progress of smart liposome achievements for anticancer drug delivery applications.
format Online
Article
Text
id pubmed-9608678
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96086782022-10-28 Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment Nikolova, Maria P. Kumar, Enamala Manoj Chavali, Murthy S. Pharmaceutics Review Liposomes are well-known nanoparticles with a non-toxic nature and the ability to incorporate both hydrophilic and hydrophobic drugs simultaneously. As modern drug delivery formulations are produced by emerging technologies, numerous advantages of liposomal drug delivery systems over conventional liposomes or free drug treatment of cancer have been reported. Recently, liposome nanocarriers have exhibited high drug loading capacity, drug protection, improved bioavailability, enhanced intercellular delivery, and better therapeutic effect because of resounding success in targeting delivery. The site targeting of smart responsive liposomes, achieved through changes in their physicochemical and morphological properties, allows for the controlled release of active compounds under certain endogenous or exogenous stimuli. In that way, the multifunctional and stimuli-responsive nanocarriers for the drug delivery of cancer therapeutics enhance the efficacy of treatment prevention and fighting over metastases, while limiting the systemic side effects on healthy tissues and organs. Since liposomes constitute promising nanocarriers for site-targeted and controlled anticancer drug release, this review focuses on the recent progress of smart liposome achievements for anticancer drug delivery applications. MDPI 2022-10-15 /pmc/articles/PMC9608678/ /pubmed/36297630 http://dx.doi.org/10.3390/pharmaceutics14102195 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nikolova, Maria P.
Kumar, Enamala Manoj
Chavali, Murthy S.
Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment
title Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment
title_full Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment
title_fullStr Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment
title_full_unstemmed Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment
title_short Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment
title_sort updates on responsive drug delivery based on liposome vehicles for cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608678/
https://www.ncbi.nlm.nih.gov/pubmed/36297630
http://dx.doi.org/10.3390/pharmaceutics14102195
work_keys_str_mv AT nikolovamariap updatesonresponsivedrugdeliverybasedonliposomevehiclesforcancertreatment
AT kumarenamalamanoj updatesonresponsivedrugdeliverybasedonliposomevehiclesforcancertreatment
AT chavalimurthys updatesonresponsivedrugdeliverybasedonliposomevehiclesforcancertreatment